This is one of the few areas where we finally have direct head-to-head human data, and the answer is more interesting than "IV is stronger."
The theoretical argument for IV is straightforward: injecting bypasses digestion entirely, avoiding breakdown by gut enzymes and bacteria, and skipping first-pass metabolism in the liver. On paper that should deliver more intact compound into circulation.
But the practical picture is messier. A retrospective study in a real-world clinical setting compared 500 mg of IV NAD+ against 500 mg of IV NR, given four consecutive days with 30-day follow-up. Tolerability differed sharply between the two: people receiving IV NAD+ reported moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions, while the IV NR group experienced only minor tingling in the tongue, jaw, and arm plus mild cramping. Those symptoms forced IV NAD+ infusions to run much slower — averaging 97 minutes versus 37 minutes for NR. All symptoms resolved once infusions finished, and neither group showed significant changes in liver enzymes, hsCRP, kidney markers, or TSH.
That last point matters: in a short study, IV didn't produce dramatic biomarker advantages to justify the cost and discomfort. Meanwhile, oral dosing has a substantial track record. Oral NR at 1,000 mg/day raised NAD+ in human peripheral blood mononuclear cells by roughly 60% after six weeks, and doses as high as 3,000 mg/day have been shown safe, producing about a five-fold increase in blood NAD+ over ten weeks. Blood levels from oral dosing typically peak three to eight hours after intake.
There's also a mechanistic wrinkle that undercuts the "IV bypasses everything" logic. Research tracing the fate of these molecules found that intravenously administered NMN and NR were rapidly broken down into nicotinamide and secreted into bile, then deamidated by gut bacteria anyway. In other words, IV delivery doesn't fully escape the same metabolic handling that oral dosing goes through.
Practical takeaway: IV NAD+ is expensive, uncomfortable for many people, requires a clinic visit, and hasn't demonstrated clear superiority over oral precursors in the limited comparative data available. If you're going the IV route, the evidence suggests IV NR is better tolerated than IV NAD+ itself. For most people, consistent oral dosing is the more practical and better-evidenced approach.
Sources for this question:
- Frontiers in Aging, "Intravenous infusion of NAD+ versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting" — https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1652582/full
- PMC version of the same study — https://pmc.ncbi.nlm.nih.gov/articles/PMC12907335/
- medRxiv, "Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults" — https://www.medrxiv.org/content/10.1101/2024.06.06.24308565.full.pdf
- Science Advances, "Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation" — https://www.science.org/doi/10.1126/sciadv.adr1538
0 comments